{"id":3041,"date":"2019-04-01T11:36:22","date_gmt":"2019-04-01T09:36:22","guid":{"rendered":"https:\/\/alzheimer.noemi.lu\/?p=3041"},"modified":"2019-04-01T11:36:22","modified_gmt":"2019-04-01T09:36:22","slug":"fundacio-ace-joins-epad-for-dementia-prevention","status":"publish","type":"post","link":"https:\/\/ep-ad.org\/index.php\/2019\/04\/01\/fundacio-ace-joins-epad-for-dementia-prevention\/","title":{"rendered":"Fundaci\u00f3 ACE joins EPAD for dementia prevention"},"content":{"rendered":"\n
\"\"<\/figure>
\n

<\/p>\n<\/div><\/div>\n\n\n\n

Fundaci\u00f3 ACE<\/a> \u2013 Barcelona Alzheimer Treatment & Research Center<\/strong>, an entity devoted to the diagnosis, treatment, research and awareness on Alzheimer’s disease, has been incorporated into EPAD<\/strong><\/a> (European Prevention of Alzheimer’s Dementia Consortium)<\/strong>, a European consortium aiming to work for the prevention of Alzheimer’s dementia through an interdisciplinary research program<\/strong>.<\/p>\n\n\n\n

Facing the evidence that Alzheimer’s disease\ncauses brain alterations prior to the onset of symptoms, this project focuses on\nthe early phases of the disease to develop actions that help to prevent and\ntreat this type of dementia<\/strong>. In recent years, research has increasingly\nfocused on this presymptomatic phase in order to offer new preventive\ntreatments and to intervene more effectively.<\/p>\n\n\n\n

EPAD is the largest public-private consortium in the field of Alzheimer’s research thanks to the participation of multiple collaborating organisations and more than 1,500 registered participants to date. Fundaci\u00f3 ACE becomes a new member of the group and one of the three representatives of Spain, together with the Pasqual Maragall Foundation research center, the Barcelona\u03b2eta Brain Research Center, and the Alzheimer’s CITA Foundation.<\/p>\n\n\n\n

Dr. Merc\u00e8 Boada<\/strong>, medical director of Fundaci\u00f3 ACE, attended, last February in Berlin a follow-up meeting of the project along with other experts from the organisation such as Dr. Agust\u00edn Ruiz<\/strong>, research director, Dr. Carla Abdelnour, attached to the Clinical Trials Unit, and Mar Buendia<\/strong>, clinical trials coordinator.<\/p>\n\n\n\n

Dr. Boada expressed satisfaction with the recent incorporation of the Foundation to the project. “In recent years, at Fundaci\u00f3 ACE we focused on the early detection of Alzheimer’s and we devoted many efforts in this direction. It is not an easy task; It is a challenge in which we keep on putting efforts day by day. This is why, we are convinced that it will be very positive to be part of a project that pools the knowledge of so many entities and experts and unites efforts in the prevention and treatment of dementia”<\/em> she comments.<\/p>\n\n\n\n

 <\/em><\/strong> <\/pre>\n\n\n\n
The challenges of EPAD<\/strong><\/p>\n\n\n\n
In order to carry out its work, EPAD faces several challenges, such as the difficulty of identifying people who may end up developing Alzheimer’s, the lack of understanding of the earliest stages of the illness or the lack of flexibility in the clinical trials development.<\/p>\n\n\n\n
To address these difficulties, the Consortium developed\nthree basic strategies:<\/p>\n\n\n\n